ABUS logo

ARBUTUS BIOPHARMA CORP

ABUSNASDAQ
🏆 #2503 by market capEarnings Nov 11US Equity
$4.69▼ $0.18 (−3.80%)
Market closed · at close
🔔
Track ABUS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.8%
7d▼ 3.5%
14d▼ 7.0%
30d▼ 7.7%
ytd▼ 2.8%
1y▲ 3.0%
🏦Market Cap
$925M
Small Cap
📈Revenue Growth (YoY)
+128.2%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
-13.6%
Thin
⚖️P/S Ratio
5.3x
Fair
Otter Score
88
Very Good

Trading Snapshot

Day Range
$4.66 – $4.77
52-Week Range
$3.50 – $5.45
Volume
$4.56B
Avg Volume
$3.08B
Shares Outstanding
197.5M
Next Earnings
Nov 22, 2026

Fundamentals Snapshot

Annual Revenue
$14M
Last Q Revenue
$1M
P/E Ratio
6.1
P/S Ratio
5.3x
EPS (TTM)
$0.78
Dividend Yield
0.00%
Dilution (1yr)
+0.9%

Why Investors Own ABUS

  • ✓High-growth profile — revenue up +35.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 56% gross margin and 7% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABUS logo

ARBUTUS BIOPHARMA CORP

ABUS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$14M▲ +128.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.4%▼ −2.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −64.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$40M▼ −39.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
191.6M▲ +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$14M▼ −$16M YoY
StockOtter · stockotter.space

About ARBUTUS BIOPHARMA CORP

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Price Target

ⓘ
Average Target
$5.28
▲ +12.7% Upside
High Target$5.99
Low Target$4.23
Based on 25 analysts

Latest News & Updates

🚀
Barron’s·2h ago

ARBUTUS BIOPHARMA CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ABUS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ARBUTUS BIOPHARMA CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.